Literature DB >> 8079830

Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice.

F Erdö1, K Török, J I Székely.   

Abstract

The aim of the present study was to examine whether interleukin-1 (IL-1) production is involved in the pathology of inflammation induced by zymosan in the air-pouch of mice. For this reason the IL-1 alpha level was determined in the air-pouch exudate by specific ELISA kit 4, 24, 48 h and 4-8 days after zymosan injection into preformed subcutaneous air-pouches in mice. Concurrently, some conventional parameters such as volume of exudate, its protein content and the total leukocyte count were also measured. The IL-1 alpha level reached its maximum 24 h after zymosan administration and remained elevated throughout the 8-day observation period. Exudation, accumulation of leukocytes and protein also were maximal on day 8. The effects of some anti-inflammatory agents have also been examined. Orally administered dexamethasone induced a dose-dependent reduction in IL-1 alpha, whereas indomethacin and IX 207-887, an IL-1-release inhibitor, failed to reduce the IL-1 alpha content in this model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8079830     DOI: 10.1007/bf01986403

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  Inhibition of interleukin-1 release by IX 207-887.

Authors:  J Schnyder; P Bollinger; T Payne
Journal:  Agents Actions       Date:  1990-06

2.  A modified mouse air pouch model for evaluating the effects of compounds on granuloma induced cartilage degradation.

Authors:  K M Bottomley; R J Griffiths; T J Rising; A Steward
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

3.  Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model.

Authors:  J Dawson; C Rordorf-Adam; T Geiger; H Towbin; S Kunz; H Nguyen; O Zingel; D Chaplin; K Vosbeck
Journal:  Agents Actions       Date:  1993-03

4.  Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. II. Identification of (tissue) macrophages as the IL-1 producing cells and the effect of anti-inflammatory drugs.

Authors:  J Dawson; C Rordorf-Adam; T Geiger; H Towbin; S Kunz; H Nguyen; O Zingel; D Chaplin; K Vosbeck
Journal:  Agents Actions       Date:  1993-03

5.  Crystal-neutrophil interactions lead to interleukin-1 synthesis.

Authors:  C J Roberge; J Grassi; R De Médicis; Y Frobert; A Lussier; P H Naccache; P E Poubelle
Journal:  Agents Actions       Date:  1991-09

Review 6.  Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism.

Authors:  C A Dinarello
Journal:  Int J Tissue React       Date:  1992

7.  The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes.

Authors:  D M Chang; P Baptiste; P H Schur
Journal:  J Rheumatol       Date:  1990-09       Impact factor: 4.666

8.  Pharmacological studies on zymosan inflammation in rats and mice. 1: Zymosan-induced paw oedema in rats and mice.

Authors:  J P Tarayre; A Delhon; M Aliaga; M Barbara; F Bruniquel; V Caillol; L Puech; N Consul; J Tisné-Versailles
Journal:  Pharmacol Res       Date:  1989 Jul-Aug       Impact factor: 7.658

9.  Induction of zymosan-air-pouch inflammation in rats and its characterization with reference to the effects of anticomplementary and anti-inflammatory agents.

Authors:  S Konno; S Tsurufuji
Journal:  Br J Pharmacol       Date:  1983-10       Impact factor: 8.739

  9 in total
  2 in total

1.  Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice.

Authors:  F A van de Loo; S Kuiper; F H van Enckevort; O J Arntz; W B van den Berg
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

2.  Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice.

Authors:  K Török; K Németh; F Erdö; P Arányi; J I Székely
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.